AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Indivior PLC

Board/Management Information Nov 15, 2024

4923_dirs_2024-11-15_d7cec154-f1a8-444e-add6-da9e8150f49c.html

Board/Management Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 3446M

Indivior PLC

15 November 2024

INDIVIOR PLC (the 'Company')

DIRECTOR DECLARATION

Richmond, VA, and Slough, UK, November 15, 2024 - The Board of Directors of Indivior PLC (Nasdaq/LSE: INDV) have agreed that Jerome Lande will continue to serve as a Non-Executive Director until December 31, 2024, whereupon he will step down from the Board.

The Company's relationship agreement with Scopia Capital Management LP ("Scopia"), otherwise due to expire on December 31, 2024, has terminated in accordance with its terms because the aggregate of Scopia's and its affiliates' interests in the issued share capital of the Company has reduced below the threshold for automatic termination. Notwithstanding that the threshold for automatic termination has been crossed, the Board and Scopia have agreed that Jerome Lande will continue to serve as a Non-Executive Director until December 31, 2024.

The Board would like to express its sincere thanks to Jerome for his significant contribution to Indivior since joining the Board in 2021.

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .

For Further Information

Investor Enquiries Jason Thompson VP, Investor Relations

Indivior PLC
+1 804 402 7123

[email protected]
Tim Owens Director, Investor Relations Indivior PLC +1 804 263 3978

[email protected]
Media Enquiries Jonathan Sibun Teneo

U.S. Media Inquiries
+44 (0)20 7353 4200

+1 804 594 0836

[email protected]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RDNQKQBKNBDBFDD

Talk to a Data Expert

Have a question? We'll get back to you promptly.